Composition for prevention and treatment on viral infectious myocarditis

A technology for viral infection and myocarditis, applied in the field of medicine, can solve the problems of non-specific treatment methods, etc., and achieve the improvement of biochemical indicators, significant effect, and good biochemical indicators

Inactive Publication Date: 2017-04-26
徐州诺克非医药科技有限公司
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Currently, there is no specific treatment, and the treatment mainly targets viral infection and myocardial inflammation

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition for prevention and treatment on viral infectious myocarditis
  • Composition for prevention and treatment on viral infectious myocarditis
  • Composition for prevention and treatment on viral infectious myocarditis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0012] The above description is only an overview of the technical solution of the present invention. In order to understand the technical means of the present invention more clearly and implement it according to the content of the description and conventional technical means in the field, the animal test examples of the present invention will be further described in detail below .

[0013] The preparation method of the compound Trefolane A involved in the present invention can be found in the literature (Trefolanes A–D with aDiterpene-Sesquiterpene Skeleton from Supercritical Fluid Extracts of Helianthus annuus L.var.AriannaOrg.Lett., 2015, 17(19), 4730–4733).

[0014] Tubeimoside A, CAS: 102040-03-9, is available in the market.

[0015] Modeling: 4-week-old clean-grade mice, weighing 7-11g, male, the ambient temperature of the animal room is 27°C-30°C, and the humidity is 35%-45%. 616 mice were randomly divided into 22 groups, 28 in each group, divided into 20 groups of drug...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a composition for prevention and treatment on viral infectious myocarditis. Active ingredients of the composition comprise Trefolane A and Tubeimoside A in a weight proportion of 1: 1 to 20: 1. Trefolane A and Tubeimoside A have good effects of improving general conditions, a survival rate, serum malondialdehyde (M DA) and serum nitric oxide (NO) of Coxsackie virus-infected myocarditis and have significant effects of prevention and treatment on Coxsackie virus-infected myocarditis.

Description

technical field [0001] The invention relates to a composition for preventing and treating viral infectious myocarditis, which belongs to the technical field of medicine. Background technique [0002] Viral myocarditis refers to localized or diffuse acute or chronic inflammatory lesions of the myocardium caused by viral infection, and belongs to infectious myocardial disease. Myocarditis occurs in about 5% of patients during the epidemic infection period of the virus, and it can also be sporadic. Clinical manifestations vary in severity. The diagnosis is considered based on a typical history of antecedent infection; corresponding clinical manifestations; evidence of myocardial injury on ECG, myocardial injury markers, and echocardiography, and the diagnosis depends on endomyocardial biopsy. Currently, there is no specific treatment, and the treatment mainly targets viral infection and myocardial inflammation. Most patients recovered after appropriate treatment, and very fe...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/047A61K31/7048A61P31/14
CPCA61K31/047A61K31/7048
Inventor 庄焕迪张文轩
Owner 徐州诺克非医药科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap